Ethic Inc. Has $498,000 Holdings in Azenta, Inc. $AZTA

Ethic Inc. lifted its stake in shares of Azenta, Inc. (NASDAQ:AZTA) by 47.7% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 16,271 shares of the company’s stock after buying an additional 5,253 shares during the quarter. Ethic Inc.’s holdings in Azenta were worth $498,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of AZTA. Mechanics Financial Corp boosted its holdings in Azenta by 77.6% during the 2nd quarter. Mechanics Financial Corp now owns 870 shares of the company’s stock worth $27,000 after acquiring an additional 380 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in Azenta by 41.6% during the 2nd quarter. Farther Finance Advisors LLC now owns 1,371 shares of the company’s stock worth $42,000 after acquiring an additional 403 shares during the last quarter. CWM LLC boosted its holdings in Azenta by 113.5% during the 2nd quarter. CWM LLC now owns 1,898 shares of the company’s stock worth $58,000 after acquiring an additional 1,009 shares during the last quarter. State of Wyoming boosted its holdings in Azenta by 77.1% during the 1st quarter. State of Wyoming now owns 2,343 shares of the company’s stock worth $81,000 after acquiring an additional 1,020 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in Azenta by 13,184.2% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,524 shares of the company’s stock worth $87,000 after acquiring an additional 2,505 shares during the last quarter. Institutional investors and hedge funds own 99.08% of the company’s stock.

Analyst Ratings Changes

AZTA has been the topic of a number of analyst reports. Stephens began coverage on shares of Azenta in a report on Tuesday, July 22nd. They set an “equal weight” rating and a $35.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Azenta in a report on Wednesday, October 8th. Raymond James Financial raised shares of Azenta from a “market perform” rating to an “outperform” rating and set a $35.00 price target on the stock in a report on Wednesday, August 6th. Finally, Evercore ISI set a $33.00 price target on shares of Azenta and gave the stock an “in-line” rating in a report on Tuesday, August 5th. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $35.75.

Azenta Price Performance

Shares of NASDAQ AZTA opened at $31.36 on Wednesday. The stock has a market capitalization of $1.44 billion, a P/E ratio of -12.96 and a beta of 1.62. Azenta, Inc. has a one year low of $23.91 and a one year high of $55.63. The firm’s 50 day simple moving average is $30.63 and its two-hundred day simple moving average is $29.79.

Azenta (NASDAQ:AZTA) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.06. The company had revenue of $143.94 million during the quarter, compared to analyst estimates of $149.64 million. Azenta had a positive return on equity of 1.35% and a negative net margin of 18.45%.The firm’s revenue was up .0% on a year-over-year basis. During the same quarter last year, the firm posted $0.14 earnings per share. As a group, equities analysts expect that Azenta, Inc. will post 0.53 earnings per share for the current fiscal year.

Azenta Company Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.